ArticleBMC veterinary research2026
Immunological response of goldfish (Carassius auratus) to recombinant pro-hepcidin and its antibacterial activity against Aeromonas hydrophila.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepcidin is a key antimicrobial peptide involved in innate immunity in fish. The present study aimed to produce recombinant pro-hepcidin from goldfish (Carassius auratus) (rpro-CuHep) and to evaluate its antibacterial activity as well as its effects on immune responses and resistance against Aeromonas hydrophila infection in goldfish.
resultsThe full-length goldfish pro-hepcidin gene was synthesized using codon optimization for Escherichia coli BL21 Rosetta and cloned into the pET28a + expression vector. Successful transformation was confirmed by Colony PCR, yielding a 287-bp fragment. Recombinant protein expression was induced with 1 mM IPTG at 37 °C for 8 h. The rpro-CuHep peptide was purified using affinity chromatography and identified as an approximately 10-kDa protein by SDS-PAGE and Western blot analysis. Antibacterial assays demonstrated that rpro-CuHep exhibited notable inhibitory activity against A. hydrophila and Streptococcus iniae. In vivo challenge experiments showed that goldfish treated with rpro-CuHep had significantly lower mortality rates following A. hydrophila infection compared to the control group. Furthermore, immune parameters including total protein, lysozyme activity, alternative complement activity (ACH50), and total immunoglobulin levels were significantly elevated in rpro-CuHep-treated fish (p < 0.05). Gene expression analysis revealed significant upregulation of interleukin-6 (IL-6) and interleukin-10 (IL-10) (p < 0.05), whereas no significant change was observed in interleukin-8 (IL-8) expression (p > 0.05).
conclusionsThe results demonstrate that rpro-CuHep possesses strong antibacterial activity and can significantly enhance immune responses and disease resistance in goldfish. These findings suggest that recombinant pro-hepcidin has potential as an effective immunostimulant and antibacterial agent for controlling bacterial infections such as A. hydrophila in aquaculture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.